U.S. National Library of MedicineNational Institutes of Health
Skip navigation
MedlinePlus Trusted Health Information for You MedlinePlus Trusted Health Information for You MedlinePlus Trusted Health Information for You
Contact Us FAQs Site Map About MedelinePlus
español

Reuters Health Information Logo

US warns Forest Labs on hypertension drug ad

Printer-friendly version Printer-friendly version

Reuters Health

Monday, September 8, 2008

WASHINGTON (Reuters) - U.S. health regulators have warned Forest Laboratories Inc for promoting its hypertension drug Bystolic to doctors without properly noting the medication's risk, according to a letter released on Monday.

An 8-page advertisement, which ran in various medical journals, also implied that the drug is better than rival products even though there is no substantial evidence to prove such claims, the U.S. Food and Drug Administration said in the letter.

"Although the journal ad does include important safety information on its second page, it omits and minimizes certain risks," wrote Thomas Abrams, head of the FDA's Division of Drug Marketing, Advertising and Communications.

Forest's ad specifically left off a warning about the drug's use in patients with congestive heart failure, the letter dated Aug. 28 said.

The drugmaker's Senior Vice President for Finance and Chief Financial Officer Frank Perier said the ad had been running in a variety of professional medical journals since January but was no longer in use.

He added the company was taking the FDA's warning seriously and planned to respond to the agency's request for company comment by Sept. 12.

The FDA letter said the New York-based drug maker's ad also made claims that the beta-blocker works better for patients who are obese, diabetic or have poor metabolism, even though clinical trials were not designed to show such an effect.

Bystolic, approved in December 2007, has been linked to a number of serious risks such as cardiac failure and chest pain, according to the letter. It is also not supposed to be used in a variety of patients, including those with various heart problems.

The FDA sends dozens of similar warning letters each year; most are resolved without further action, although the FDA can impose fines or other penalties.

The letter was released on the FDA website Monday at http://www.fda.gov/cder/warn/2008/Bystolic-wl.pdf.


Reuters Health

Copyright © 2008 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

Related News:
More News on this Date

Related MedlinePlus Pages: